Table 2.

Multivariate Cox Regression of Rehospitalization for Complicated Recurrent Peptic Ulcers with a Time Lag of More than 120 Days in the Overall Study Group

Variable	HR	95% CI	p-value
Time to H. pylori eradication*
>120 days vs ≤120 days	1.52	1.13–2.04	0.006
Age, yr
20–49 vs ≥70	0.23	0.15–0.35	<0.001
50–69 vs ≥70	0.44	0.32–0.62	<0.001
Sex
Male vs female	1.25	0.91–1.73	0.167
Gastroduodenal ulcer history	1.40	0.89–2.22	0.149
Ulcer position
Gastric ulcer vs duodenal ulcer	1.40	1.03–1.89	0.031
Peptic ulcer† vs duodenal ulcer	0.86	0.29–2.51	0.782
Comorbidities
DM	1.06	0.71–1.58	0.782
CHF	0.75	0.29–1.91	0.542
CAD	1.05	0.72–1.55	0.788
COPD	0.84	0.57–1.24	0.375
Medications
PPIs or H2-blockers	2.30	1.65–3.19	<0.001
Aspirin	0.50	0.26–0.93	0.029
NSAIDs	4.18	3.12–5.59	<0.001
COX-2 specific inhibitors	2.63	1.72–4.04	<0.001
Steroids	0.68	0.37–1.24	0.209
Clopidogrel	0.85	0.31–2.36	0.753
Ticlopidine	0.37	0.05–2.71	0.326
Warfarin	3.67	0.82–16.51	0.090

HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus; CHF, congestive heart failure; CAD, cardiovascular disease; COPD, chronic obstructive pulmonary disease; PPIs, proton pump inhibitors; H₂-blockers, histamine receptor-2 blockers; NSAIDs, nonsteroidal anti-inflammatory drugs; COX-2, cyclooxygenase-2.

^*Time of peptic ulcer diagnosis to the Helicobacter pylori eradication therapy;

^†Peptic ulcer includes gastric ulcer and duodenal ulcer.